Extracellular vesicles‐derived miR‐150‐5p secreted by adipose‐derived mesenchymal stem cells inhibits CXCL1 expression to attenuate hepatic fibrosis

Du, Zhifeng; Wu, Tianchong; Liu, Linsen; Luo, Biwei; Wei, Cuifeng

doi:10.1111/jcmm.16119

Cited by 44 publications

(26 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…EVs from AD-MSC engineered to over-produce miR-122 (a known inhibitor of fibrosis) suppressed proliferation and collagen production in activated human or mouse HSC with suppressed expression of P4HA1 , IGF-1R and CCNG1 target genes [ 275 ]. Administration of miR-122-enriched AD-MSC EVs in CCl 4 -treated mice resulted in attenuation of hepatic fibrosis, suppression of hepatic TGF-β1 and αSMA expression, and inhibition of serum ALT, hyaluronan, type III procollagen, aspartate transaminase and liver hydroxyproline [ 275 ] while mir-150-5p-enriched AD-MSC EVs were anti-fibrotic due to targeting of CXCL1 [ 276 ]. Similarly, EVs from miR-181-5p-over-expressing AD-MSCs were antifibrogenic in vitro and anti-fibrotic in vivo at least in part due to down regulation of STAT3 and Bcl2 , stimulation of autophagy, and suppression of fibrogenic gene expression [ 277 ].…”

Section: Hepatic Fibrosismentioning

confidence: 99%

Extracellular Vesicles in Organ Fibrosis: Mechanisms, Therapies, and Diagnostics

Brigstock

2021

Cells

View full text Add to dashboard Cite

Fibrosis is the unrelenting deposition of excessively large amounts of insoluble interstitial collagen due to profound matrigenic activities of wound-associated myofibroblasts during chronic injury in diverse tissues and organs. It is a highly debilitating pathology that affects millions of people globally and leads to decreased function of vital organs and increased risk of cancer and end-stage organ disease. Extracellular vesicles (EVs) produced within the chronic wound environment have emerged as important vehicles for conveying pro-fibrotic signals between many of the cell types involved in driving the fibrotic response. On the other hand, EVs from sources such as stem cells, uninjured parenchymal cells, and circulation have in vitro and in vivo anti-fibrotic activities that have provided novel and much-needed therapeutic options. Finally, EVs in body fluids of fibrotic individuals contain cargo components that may have utility as fibrosis biomarkers, which could circumvent current obstacles to fibrosis measurement in the clinic, allowing fibrosis stage, progression, or regression to be determined in a manner that is accurate, safe, minimally-invasive, and conducive to repetitive testing. This review highlights the rapid and recent progress in our understanding of EV-mediated fibrotic pathogenesis, anti-fibrotic therapy, and fibrosis staging in the lung, kidney, heart, liver, pancreas, and skin.

show abstract

Section: Hepatic Fibrosismentioning

confidence: 99%

Extracellular Vesicles in Organ Fibrosis: Mechanisms, Therapies, and Diagnostics

Brigstock

2021

Cells

View full text Add to dashboard Cite

show abstract

“…Anti-oxidative glutathione peroxidase 1 delivered by the MSC-exosomes decreased oxidative stress and increased hepatocyte proliferation in CCl 4 -injured liver [ 145 ]. Furthermore, the treatment of MSCs-EV containing miR-150-5p reduced the expression of CXC chemokine-ligand-1, one of the profibrotic chemokines in HSCs, and attenuated liver fibrosis [ 146 ]. The miR-1246 contained in MSC-exosomes was shown to protect hepatocytes from ischemia-reperfusion injury and modulate the balance of regulatory T cells and Th17 cells to suppress inflammation and maintain immune tolerance [ 147 ].…”

Section: Msc Cell-free Therapy For Liver Fibrosismentioning

confidence: 99%

Mesenchymal Stem Cells Influence Activation of Hepatic Stellate Cells, and Constitute a Promising Therapy for Liver Fibrosis

et al. 2021

View full text Add to dashboard Cite

Liver fibrosis is a common feature of chronic liver disease. Activated hepatic stellate cells (HSCs) are the main drivers of extracellular matrix accumulation in liver fibrosis. Hence, a strategy for regulating HSC activation is crucial in treating liver fibrosis. Mesenchymal stem cells (MSCs) are multipotent stem cells derived from various post-natal organs. Therapeutic approaches involving MSCs have been studied extensively in various diseases, including liver disease. MSCs modulate hepatic inflammation and fibrosis and/or differentiate into hepatocytes by interacting directly with immune cells, HSCs, and hepatocytes and secreting modulators, thereby contributing to reduced liver fibrosis. Cell-free therapy including MSC-released secretomes and extracellular vesicles has elicited extensive attention because they could overcome MSC transplantation limitations. Herein, we provide basic information on hepatic fibrogenesis and the therapeutic potential of MSCs. We also review findings presenting the effects of MSC itself and MSC-based cell-free treatments in liver fibrosis, focusing on HSC activation. Growing evidence supports the anti-fibrotic function of either MSC itself or MSC modulators, although the mechanism underpinning their effects on liver fibrosis has not been established. Further studies are required to investigate the detailed mechanism explaining their functions to expand MSC therapies using the cell itself and cell-free treatments for liver fibrosis.

show abstract

“…Micro RNAs (miRNAs, or miRs) are small non-coding RNA molecules (about 22 nucleotides) that change gene expression at the post-transcriptional level, leading to changes in protein synthesis. MiR-150 is a representative anti-fibrotic miRNA, which can inhibit the activation of hepatic stellate cells through the inhibition of C-X-C motif chemokine ligand 1 (CXCL1), and is a natural component of ASCs EVs[ 35 ]. Paik et al [ 36 ] transfected ASCs with miR-150 to explore whether additional miR-150 secretion could boost the anti-fibrotic ability.…”

Section: Ways To Enhance Ascs Therapeutic Performancementioning

confidence: 99%

Application of adipose-derived stem cells in treating fibrosis

Li¹,

Wang²,

Li³

et al. 2021

WJSC

View full text Add to dashboard Cite

Fibrosis is the hyperactivation of fibroblasts that results in excessive accumulation of extracellular matrix, which is involved in numerous pathological changes and diseases. Adipose-derived stem cells (ASCs) are promising seed cells for regenerative medicine due to their bountiful source, low immunogenicity and lack of ethical issues. Their anti-fibrosis, immunomodulation, angiogenesis and other therapeutic effects have made them suitable for treating fibrosis-related diseases. Here, we review the literature on ASCs treating fibrosis, elaborate and discuss their mechanisms of action, changes in disease environment, ways to enhance therapeutic effects, as well as current preclinical and clinical studies, in order to provide a general picture of ASCs treating fibrotic diseases.

show abstract

Extracellular vesicles‐derived miR‐150‐5p secreted by adipose‐derived mesenchymal stem cells inhibits CXCL1 expression to attenuate hepatic fibrosis

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 44 publications

References 43 publications

Extracellular Vesicles in Organ Fibrosis: Mechanisms, Therapies, and Diagnostics

Extracellular Vesicles in Organ Fibrosis: Mechanisms, Therapies, and Diagnostics

Mesenchymal Stem Cells Influence Activation of Hepatic Stellate Cells, and Constitute a Promising Therapy for Liver Fibrosis

Application of adipose-derived stem cells in treating fibrosis

Contact Info

Product

Resources

About